Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding of sugammadex for reversal of rocuronium-induced neuromuscular block in morbidly obese patients
2009-016857-16Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Apr 2010
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of Sugammadex in class III obesity and neuromuscular block (NMB) (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Dose-response relationship of sugammadex in morbidly obese patients. Started Apr 2010; status: completed.
02
Drugs
Sugammadex
03
Conditions
class III obesityneuromuscular block (NMB)
Beyond the preview
Go deeper on 2009-016857-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016857-16.